Clinical study on feverfew supplement announced by Kaiser-Permanente
The double blind, placebo-controlled study will evaluate the effectiveness
of Migra-LieveTM on migraine frequency
and severity over a three month period. Developed by Natural Science
Corporation of America, Migra-LieveTM
is a patent pending combination of magnesium, riboflavin, and a proprietary
standardized extract of feverfew. The product is marketed to physicians
and pharmacists, and is currently being used by a number of doctors,
hospitals, and clinics, including the New York Headache Center in New
York City.
PR Newswire, January 26, 2000.
|
